Invasive Versus Conservative Strategy in Older Adults ≥75 Years of Age With Non-ST-segment-Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Nov 4, 2024DOI: 10.1161/jaha.124.036151Comparative StudyAHA
Written by: Amit RoutMohamad B MoumnehKriti KalraSahib SinghAakash GargVijay KunadianSimone BiscagliaMohamad A AlkhouliJennifer A RymerWayne B BatchelorMichael G NannaAbdulla A Damluji
Find these authors on Roon
JR
Dr. Jennifer Rymer
Interventional & Peripheral Cards · Duke University
The authors declare that all supporting data are available within the article and its online supplementary files. We searched MEDLINE, EMBASE, and Cochrane databases for RCTs published between January 1, 1990, and October 1, 2023, for studies comparing an invasive versus conservative strategy for older patients with NSTE‐ACS. Consistent with recommendations from the American Heart Association, American College of Cardiology, and American Geriatric Society,20 the age cutoff ≥75 years old was used for defining the older adult population in this study. An invasive strategy was defined as the use of routine invasive coronary angiography with subsequent revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), as appropriate. A conservative strategy was defined as medical therapy or a selective invasive strategy only. We used the search headings such as “invasive,” “medical therapy,” “selective invasive”, “conservative,” “NSTE‐ACS,” “NSTEMI,” “older adults,” and “elderly” in different combinations. The study inclusion criteria were as follows: RCTs or subanalyses of RCTs comparing invasive versus conservative strategies, mean age of the study patients ≥75 years, median follow‐up of at least 1 month, and reporting at least one clinical end point of interest. The exclusion criteria were nonrandomized study design and inclusion of patients with ST‐segment–elevation‐ACS.Two reviewers (A.R. and S.S.) independently screened study reports for eligibility, assessed the risk of bias, and collected data from each eligible study using the aforementioned criteria. Disagreements were resolved with a discussion with another investigator (A.G.). The following data from the included studies were recorded: study characteristics, study design, year of publication, inclusion and exclusion criteria, sample size, follow‐up period, primary and secondary end point definitions, baseline patient characteristics, and event rate of outcomes of interest. Prespecified outcomes of interest were the composite of death or MI and the individual end points of all‐cause death, cardiovascular death, MI, repeat revascularization (either PCI or CABG), stroke, and major bleeding at maximal available follow‐up. Outcomes were defined as per individual study protocol.This meta‐analysis was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines.21 Statistical analysis was performed using the Cochrane Review Manager, version 5.4.22, 23 The pooled odds ratio (OR) and 95% CI were calculated using fixed‐effects models with the Mantel–Haenszel method for each clinical outcome. We used the fixed‐effects model to estimates the overall average effect regardless of heterogeneity.24 P values were 2 tailed and the threshold for statistical significance level set ≤0.05. The consistency and heterogeneity were assessed by calculating the inconsistency factor (I2) statistic. Heterogeneity was considered low if I2<25%, moderate if I2 between 25% to 50%, and high if I2>50%. Forest plots were generated to demonstrate the relative effect size of the invasive versus conservative strategy.
RESULTS
The initial search yielded a total of 944 studies, out of which nine studies met the inclusion criteria. Figure 1 illustrates the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses schema diagram for the search strategy. A total of 2429 patients, with 1201 patients in the invasive strategy and 1201 patients in the conservative strategy, were included in the final analysis.6, 7, 8, 11, 12, 13, 25, 26, 27 Of the selected studies, 5 studies were independent RCTs; 1 study was a RCT subgroup (TACTICS TIMI 18 [Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy Thrombolysis in Myocardial Infarction 18]) and the results of the remaining 3 studies were derived from age‐stratified patient‐level pooled analysis (FRISC II [Fragmin and Fast Revascularization During Instability in Coronary Artery Disease]; ICTUS [Invasive Versus Conservative Treatment in Unstable Coronary Syndromes]; RITA‐3 [Randomized Intervention Trial of Unstable Angina]).28, 29 The MOSCA‐FRAIL (Comorbilidades en el Síndrome Coronario Agudo–Invasive and Conservative Strategies in Elderly Frail Patients With Non‐STEMI) trial did not provide numerical outcomes and was excluded from the analysis.30 The conservative approach in 6 trials involved optimal medical therapy plus a selective invasive strategy, whereas in 3 trials, it was exclusively optimal medical therapy.PRISMA indicates Preferred Reporting Items for Systematic Reviews and Meta‐Analyses; and RCT, randomized controlled trial.Table 1 provides an overview of the major inclusion and exclusion criteria and the primary end point of the incorporated studies. Table 2 illustrates patients' baseline demographic and clinical characteristics across the included trials. One study did not have baseline characteristics disclosed. The mean age of the study population was 81 years, and 56% of patients were male. The included studies did not differ significantly according to baseline characteristics. The mean follow‐up duration was 21.4 months with a median of 12 months [interquartile range 12–24]. Prior history of MI was documented in almost 35% of the study population. Eight out of 9 studies had data on invasive angiograms and revascularization. A diagnostic angiogram was performed in 94% of patients in the invasive strategy and 17% in the conservative approach. The revascularization rate was 55% in the invasive group and 12% in the conservative group.Inclusion, Exclusion, and Primary End Points of Included TrialsRandomized controlled, multicenter,open labeledNSTE‐ACS, ischemic symptoms, ECG changes or elevated troponin I, troponin T, or creatinine kinase myocardial bandACS indicates acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; MI, myocardial infarction; NSTE‐ACS, non–ST‐segment–elevation acute coronary syndrome; and STE‐ACS, ST‐segment–elevation acute coronary syndrome.*Criteria and outcomes from individual trials rather than subanalysis used in this meta‐analysis.Baseline Characteristics of Included TrialsCABG indicates coronary artery bypass graft; Cath, catheterization; CS, conservative strategy; IS, invasive strategy; MI, myocardial infarction; PCI, percutaneous coronary intervention; ST segment depression; and Trop, troponin.Both invasive and conservative.Figures 2 and 3 present ORs and 95% CIs for the comparison of participants in the invasive group versus the conservative group using the fixed‐effects models with the Mantel–Haenszel method. The composite end point of death or MI was reported across 7 RCTs for a sum of 1866 patients. Compared with the conservative strategy, the invasive strategy was associated with a significantly reduced risk of death or MI (OR, 0.67 [95% CI, 0.54–0.83], P<0.001), with no significant heterogeneity among the included studies (I2=0%) (Figure 2A). The risk of MI was reported by all 9 trials, with a total of 402 MI events (157 in invasive and 245 in conservative strategy) in 2459 patients. The risk of MI was significantly reduced with an invasive strategy compared with a conservative strategy (OR, 0.56 [95% CI, 0.45–0.70], P<0.001); however, the results were associated with moderate heterogeneity (I2=34%) among the studies included (Figure 2B). Similarly, repeat revascularization was reported by 5 studies with 1312 patients, and an invasive strategy was associated with a significantly reduced risk (OR, 0.27 [95% CI, 0.16–0.48], P<0.001) compared with a conservative strategy, with no significant heterogeneity among studies (I2=0%) (Figure 3A).A, Forest plot illustrating the odds ratio for death or myocardial infarction4, 12, 13, 28, 29; B, Forest plot illustrating the odds ratio for myocardial infarction4, 11, 12, 13, 28, 29; C, Forest plot illustrating the odds ratio for all‐cause death4, 11, 12, 13, 28, 31; D, Forest plot illustrating the odds ratio for cardiovascular death.4, 12, 29 ACS indicates acute coronary syndrome; df, degrees of freedom; FIR, Fast Revascularization During Instability in Coronary Artery Disease; I2, inconsistency factor; M‐H, Mantel–Haenszel; MOSCA, Comorbilidades en el Síndrome Coronario Agudo; MOSCA‐FRAIL, Comorbilidades en el Síndrome Coronario Agudo–Invasive and Conservative Strategies in Elderly Frail Patients With Non‐STEMI; RINCAL, Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes; and TACTICS TIMI 18, Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy–Thrombolysis in Myocardial Infarction 18.A, Forest plot illustrating the odds ratio for repeat revascularization4, 11, 12, 13; B, Forest plot illustrating the odds ratio for stroke4, 11, 12, 13, 28; C, Forest plot illustrating the odds ratio for major bleeding.4, 11, 12, 13, 28 ACS indicates acute coronary syndrome; df, degrees of freedom; I2, inconsistency factor; M‐H, Mantel–Haenszel; MOSCA, Comorbilidades en el Síndrome Coronario Agudo; RINCAL, Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes; and TACTICS TIMI 18, Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy–Thrombolysis in Myocardial Infarction 18.All‐cause and cardiovascular deaths were reported in 6 (1590 patients) and 5 (1432 patients) studies, respectively. There was a total of 284 deaths reported in 1590 patients, with 132 in the invasive group and 152 in the conservative group; however, there was no significant difference in odds ratio between the invasive and conservative strategies in terms of all‐cause death (OR, 0.84 [95% CI, 0.65–1.10], P=0.21) (Figure 2C). Similarly, there was no significant difference between the 2 groups in terms of cardiovascular death (OR, 0.85 [95% CI, 0.63–1.15], P=0.30) (Figure 2D). The results had no significant heterogeneity among the studies included in the analysis (I2=0%). Five studies reported the risk of stroke, and there was no difference in OR (OR, 0.74 [95% CI, 0.38–1.47], P=0.39) between the 2 strategies (Figure 3B). The risk of major bleeding was reported by 6 studies with 80 events in 1590 patients. Results were insufficient to conclusively determine whether the invasive group effected bleeding compared with the conservative group (OR, 1.24 [95% CI, 0.42–3.66], P=0.70), and were associated with high heterogeneity (I2 = 73%) among the included trials (Figure 3C). Because of small number of events and the concern of over certainty in the results, the cumulative OR for the influence of invasive group compared with the conservative group on clinical outcomes calculated using the exact method for fixed effects analysis and the Bayesian binomial regression is presented in Table S1. These methods provide a reliable quantification of uncertainty, and the Bayesian binomial regression offers a probabilistic uncertainty given a specific prior. The deviation among study‐specific effects on the (log) relative risk scale and associated CIs around such measures of deviation is presented in Table S3.
DISCUSSION
In this updated meta‐analysis of RCTs of older patients (≥75 years) presenting with NSTE‐ACS, we demonstrate a clear benefit for an early invasive approach compared with a conservative approach. Specifically, an invasive strategy led to a significant reduction in the composite of death or MI in older patients compared with a conservative management strategy, as well as improvements in the incidence of subsequent revascularization and MI alone. Importantly, these improvements did not come at the expense of increased bleeding risk, which was statistically similar between the invasive and conservative groups. Although these small studies enrolling older patients showed no difference in overall mortality, revascularization appeared to mostly benefit older patients by reducing combined risk of death with MI or repeat revascularization. Taken together, these findings support an invasive strategy as the first‐line approach for older adults presenting with NSTE‐ACS.The present meta‐analysis builds upon the existing literature by confirming the benefit of an invasive strategy for older adults with NSTE‐ACS for composite ischemic end points, as well as certain individual ischemic components such as MI and subsequent revascularization. Clinical trials, such as the FRISC II, RITA, and TACTICS–TIMI 18, highlight the superiority of the invasive approach on composite outcomes and demonstrate the efficacy of early revascularization in older adults with NSTE‐ACS.6, 7, 8 Although the ICTUS trial reported no difference in mortality outcomes, the pooled data analysis from the FRISC II, ICTUS, and RITA trials, revealed a pronounced reduction in cardiovascular death or MI and MI alone, especially among patients ≥75 years old.7, 8, 25, 29 The pooled analysis indicated that the advantages of the early invasive strategy were primarily observed in the cohort of patients aged ≥65 years rather than in the younger group.29 This is further corroborated by the TIMI IIIB trial, which demonstrated a significant reduction in death or MI in patients aged >65 at 1‐year follow‐up.31, 32 The After Eighty study showed similar findings and demonstrated a significant reduction in the composite of death, MI, revascularization, and stroke in the invasive arm but not in the optimal medical therapy group.11 The recent FIRE (Functional Assessment in Elderly MI Patients With Multivessel Disease) trial further supports the efficacy of invasive strategy among older adults ≥75 years of age receiving complete or culprit‐only PCI.33 In this study, older patients receiving physiology‐guided complete revascularization had a lower risk of the composite of death, MI, stroke, and revascularization at 1‐year follow‐up. Consistent with the present analysis, the 80+ study showed a numerical decrease in the risk of MI and revascularization in the invasive approach arm, although this did not reach a statistically significant number.13 Similarly, the RINCAL trial demonstrated a notable numerical decrease in MI and revascularization in the invasive arm without reaching statistical significance.12 In contrast, the findings from the VANQWISH (Veterans Affairs Non–Q‐Wave Infarction Strategies in Hospital) trial diverged from ours as they showed no difference in cumulative mortality or nonfatal MI on long‐term follow‐up between invasive and conservative strategies.32 This can be explained by the small sample size of the study (n=138 in the invasive group and n=123 in the conservative group), which might have reduced the power of the findings.Our results indicate no significant difference in the risk of major bleeding between invasive and conservative strategies. These findings were consistent with results from prior literature.34, 35, 36 Although a post hoc analysis of the TACTICS TIMI 18 trial found an increased risk of significant bleeding in patients aged ≥75 years old,6 it is important to note that patients in this study received glycoprotein IIb/IIIa inhibitors in addition to heparin. Glycoprotein IIb/IIIa inhibitors, which can be used with anticoagulants as an adjunct therapy for heavy thrombus burden, are known to increase the risk of bleeding.37 A number of observational studies on older patients with NSTE‐ACS, such as the SILVER‐AMI (Comprehensive Evaluation of Risk Factors in Older Patients With Acute Myocardial Infarction) have demonstrated high bleeding risks that might result in their readmission.38 Our results are important as they serve as reassurance that invasive strategies in this subset of patients are safe and do not increase the risk of major bleeding. The high uptake of transradial PCI in the past decade likely contributed to lower bleeding and vascular complications with an invasive strategy observed in more recent trials.In our meta‐analysis, we found a trend toward mortality reduction in patients undergoing an invasive strategy; however, it failed to reach statistical significance. This parallels and aligns with studies that have similarly indicated a nonsignificant decrease in all‐cause mortality with the invasive approach when compared with conservative strategy.39, 40, 41 Similar results were also found in studies that showed statistical significance between the invasive and conservative strategies in this patient population in terms of all‐cause mortality.42, 43, 44Recently published long‐term outcomes (follow‐up 5.3 years) of the After Eighty study showed reduction in primary end point (composite of MI, need for urgent revascularization, stroke, and death) in the invasive arm. Further, the invasive strategy was associated with a significant gain in event‐free survival of 276 days at 5 years.45 In contrast, the MOSCA‐FRAIL trial compared conservative and invasive strategies in patients aged ≥70 years with NSTEMI. This trial failed to show any notable difference in days alive and out of the hospital in patients in the invasive versus conservative arms.31 Achieving measurable reductions in overall mortality among older adults continues to be challenging. Several factors may account for conflicting results. First, revascularization was performed in only 55% of our invasive strategy patient cohort; if the treatment benefit of an invasive approach is presumably from revascularization, the relatively low rate of revascularization in the invasive group would attenuate the results observed. Second, the lack of morbidity benefit can be related to the choice of not or inability to pursue a complete revascularization. Moreover, a proportion of the trials included in our analysis permitted a selective invasive strategy.6, 25 This allowed revascularization “as required” in the conservative arm as well. This is in stark contrast to registry data, wherein mortality reduction in the invasive cohort was predominantly seen against patients receiving medical therapy only.46, 47 Additionally, the management of NSTE‐ACS in older adults is nuanced and complex due to a multitude of competing risks often observed at advanced age.10, 48 For example, the presence of geriatric syndromes like multimorbidity, polypharmacy, frailty, disability, cognitive impairment, and functional decline, influences the short‐ and long‐term outcomes of revascularization procedures.5, 10, 48, 49 Frailty has been associated with worse cardiovascular outcomes and increased morbidity and mortality in the older adult population with stable ischemic heart disease and NSTE‐ACS.50, 51, 52 Observational studies have shown that frail patients still benefit from revascularization procedures.50 This is further compounded by multimorbidity, which reflects the simultaneous presence of 2 or more cardiovascular or noncardiovascular comorbidities. Cardiovascular comorbidities may include hypertension, heart failure, stroke, peripheral vascular disease, and atrial fibrillation. Noncardiovascular comorbidities that influence outcomes may include obstructive lung disease, chronic kidney disease, and diabetes, all of which contribute to increased risk of adverse events and negative outcomes.5, 49, 53 A stepwise increase in mortality risk with an increase in frailty and comorbidity burden has been identified in older patients with ACS.54, 55 These may confound or blunt the tangible benefits of invasive management in this patient population.55, 56 However, these same patients have more complex anatomic disease and may derive more benefit from revascularization procedures than younger patients, albeit at a great risk for complications. For these reasons, clinical trials enrolling older adults with frailty and morbidity will fill these gaps in knowledge.Our results align with a recent patient‐level meta‐analysis by Kotanidis et al., which demonstrated a reduced risk of repeat MI or urgent revascularization in the invasive group compared with the conservative group among older adults aged ≥70 years. However, unlike our study, which included participants aged ≥75 years, that meta‐analysis did not show a statistically significant difference between the groups in terms of reduced all‐cause mortality or MI. This discrepancy is likely due to differences in inclusion criteria, as our study incorporated the TACTICS TIMI‐18 and FIR (Fast Revascularization During Instability in Coronary Artery Disease) trials.57Although providing pivotal insights on the benefit of revascularization in older adults, this meta‐analysis has limitations. Although we included 9 trials, our sample size was limited to 2429 patients. This reemphasizes the underrepresentation of older adults in RCTs and the dearth of evidence that limits generalizability to those with high burden of frailty, multimorbidity, polypharmacy, and other geriatric conditions. Additionally, we used trial‐level data instead of patient‐level data, which would be useful in further baseline characteristics‐adjusted analysis. Another limitation to highlight includes the heterogeneity among the trials and associated data. There was moderate heterogeneity (I2=37%) among the included studies. This can be partially attributable to the inclusion of the MOSCA study, which had numerically higher MI in the invasive arm. The exclusion of this trial from the analysis improved the heterogeneity among the studies (I2=0%). Moreover, there was significant heterogeneity noted for the bleeding end point (I2=73%), which might compromise our ability to render conclusions. The inclusion of selective invasive strategies in the control arm could have introduced bias that may favor conservative management. Only 3 trials had “only optimal medical therapy” as their conservative arm, which limits the comparator group. Despite this limitation, an invasive strategy was still associated with improved outcomes including the composite of death and MI, as well as MI alone and subsequent revascularization—all important outcomes for older adults. Outcomes beyond major adverse cardiovascular events were not included in trials. This emphasizes the need to study health‐related quality of life, disability, time at home, and other important noncardiovascular outcomes in future trials enrolling the older adult populations. Furthermore, the use of revascularization with either PCI or CABG was approximately 55% in the invasive strategy. This precludes the identification of the true benefit of revascularization in the older adult population. Moreover, 4 of the included trials are subanalysis of the original trials, and 2 of the recent trials were terminated early and were individually underpowered due to small sample size. Another limitation is that the included studies did not identify the type of MI. Type II MI is known to have worse prognosis than type I. It is possible that the lack of statistically significant mortality reduction is due to a proportion of the included patients having type II MI and hence less than anticipated mortality benefit from the invasive strategy. Finally, some trials included in this analysis are almost 2 decades old. With improvement in PCI techniques, newer generation stents, and potent P2Y12 inhibitors, outcomes with revascularization are likely to continue to improve.
CONCLUSIONS
In older patients ≥75 years old with NSTE‐ACS, an invasive strategy reduced the risk of a composite of death and MI, MI, and subsequent revascularization when compared with a conservative strategy alone. Age alone should not preclude older adults from revascularization strategies, and more nuanced geriatric and cardiovascular assessments are needed. Older adults with higher burden of geriatric conditions should be included in future trials to improve generalizability to this growing population.
Sources of Funding
Dr Damluji receives research funding from the Pepper Scholars Program of the Johns Hopkins University Claude D. Pepper Older Americans Independence Center funded by the National Institute on Aging P30‐AG021334 and receives mentored patient‐oriented research career development award from the National Heart, Lung, and Blood Institute K23‐HL153771‐01.